$-0.64 EPS Expected for Zynerba Pharmaceuticals, Inc. (ZYNE); 2 Bullish Analysts Covering Nevada Copper Corp. (TSE:NCU)

April 17, 2018 - By Vivian Currie

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Logo

Among 2 analysts covering Nevada Copper Corp. (TSE:NCU), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nevada Copper Corp. had 5 analyst reports since August 4, 2015 according to SRatingsIntel. Scotia Capital maintained the stock with “Outperform” rating in Monday, August 24 report. On Tuesday, August 4 the stock rating was maintained by Scotia Capital with “Outperform”. See Nevada Copper Corp. (TSE:NCU) latest ratings:

Analysts expect Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) to report $-0.64 EPS on May, 8.They anticipate $0.04 EPS change or 6.67% from last quarter’s $-0.6 EPS. After having $-0.60 EPS previously, Zynerba Pharmaceuticals, Inc.’s analysts see 6.67% EPS growth. The stock increased 3.79% or $0.38 during the last trading session, reaching $10.4. About 287,568 shares traded. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has declined 59.88% since April 17, 2017 and is downtrending. It has underperformed by 71.43% the S&P500.

Nevada Copper Corp., a development stage mining company, identifies, acquires, explores for, and develops copper and other mineral properties primarily in the United States. The company has market cap of $302.70 million. It explores for copper, gold, silver, and iron ores. It currently has negative earnings. The firm primarily focuses on the development of its 100% owned Pumpkin Hollow copper property that includes a contiguous 26 square mile land package comprising patented and unpatented claims located in north-western Nevada.

The stock increased 4.62% or $0.03 during the last trading session, reaching $0.68. About 3,000 shares traded. Nevada Copper Corp. (TSE:NCU) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company has market cap of $141.04 million. The Company’s product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. It currently has negative earnings. The firm was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.